RecruitingNCT04344769
Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sponsor
Mayo Clinic
Enrollment
40 participants
Start Date
Oct 4, 2019
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to characterize oxidative stress and the Nrf2 antioxidant response in early stages of Autosomal Dominant Polycystic Kidney Disease (ADPKD), while identifying candidate biomarkers.
Eligibility
Min Age: 18 YearsMax Age: 30 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with autosomal dominant polycystic kidney disease. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 30 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04344769
Related Trials
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT0690255875 locations
Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease
NCT0722836415 locations
Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)
NCT0493993549 locations
NOX4 and Related Biomarkers in ADPKD
NCT046306131 location
Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease
NCT064358582 locations